Regeneron Pharmaceuticals Inc. (REGN) News
Filter REGN News Items
REGN News Results
|Loading, please wait...
REGN News Highlights
- For REGN, its 30 day story count is now at 23.
- Over the past 26 days, the trend for REGN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about REGN are CRS, ASH and CR.
Latest REGN News From Around the Web
Below are the latest news stories about REGENERON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate REGN as an investment opportunity.
(Bloomberg) -- Regeneron Pharmaceuticals Inc. rose the most in almost two months after a court ruled that the drugmaker’s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc. Most Read from BloombergThe Late-Night Email to Tim Cook That Set the Apple Watch Saga in MotionChinese Carmaker Overtakes Tesla as World’s Most Popular EV MakerBridgewater CEO’s Past Office Romance Led to Favoritism ClaimsXiaomi Unveils Its First EV, With Ambition to Be China’s Porsche o
Understandably, with the innovation sector printing a remarkable performance, all eyes have centered on Nasdaq-100 stocks.
Can the stock continue its market-beating ways?
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK
Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.
TARRYTOWN, N.Y., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's
Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
With a price-to-earnings (or "P/E") ratio of 22.9x Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) may be sending...
You can pick these players up for a great price right now.
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.